Hepatitis c virus infection: Diagnosis, natural course and therapy

Kidney and Blood Pressure Research

Volumn 19, Issue 3-4, 1996, Pages 215-219

  Tillmann, Hans L ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hemodialysis; Hepatitis C; Interferon; Polymerase chain reaction; Viral hepatitis

Indexed keywords

AMINOTRANSFERASE; FERRITIN; HEPATITIS C ANTIBODY; INTERFERON; RIBAVIRIN; VIRUS RNA;

ANTIBODY DETECTION; AUTOIMMUNITY; CONFERENCE PAPER; DISEASE COURSE; GENOTYPE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REINFECTION; RNA VIRUS; SIDE EFFECT; VIREMIA; VIRUS CARRIER;

CHRONIC DISEASE; DNA, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; RENAL DIALYSIS;

EID: 0029798023     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000174077     Document Type: Article

References (90)

1. Takamizawa A. Mori C. Fukc I, Manabc S. Murakami S, Fujita J. Onishi E. Andoh T. Yoshida I. Okayama H: Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991;65:1105-1113.
2. Han JH. Shyamala V. Richman KH. Brauer MJ, Irvine B. Urdea MS, Tckamp-Olson P. Kuo G. Choo QL, Houghton M: Characterization of the terminal regions of hepatitis C viral RNA: Identification of conserv ed sequences in the 5' untranslated region and poly(A) tails at the 3' end. Proc Natl Acad Sci USA 1991;88:1711-1715.
3. Nasoff MS. Zebedec SL, lnchauspe G. Prince AM: Identification of an immunodominant epitope within the capsid protein of hepatitis C virus. Proc Natl Acad Sci USA 1991 188:5462-5466.
4. Burk J. Purcell RH. Miller RH: Sequence analysis of the core gene of 14 hepatitis C genotypes. Proc Natl Acad Sci USA 1994:91:8239-8243.
5. Houghton M. Weiner A. Han J. Kuo G, Choo QL: Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. Hepatology 1991:14: 381-388.
6. Cirakoui A. Wychowski C, Lin C. Feinstone SM. Rice CM: Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993:67:1385-1395.
7. Grakoui A. McCourt DM. Wychowski C. Feinstone SM. Rice CM: Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993:67:2832-2843.
8. Chung RT. Kaplan LM: Identification and characterization of a hepatitis C virus specific RNA dependent RNA polymerase activity from extracts of infected liver tissue (abstract). Hepatology 1992:16:132.
9. Kaito M. Watanabe S. Tsukiyama-Kohara K. Yamaguchi K. Kobayashi Y. Konishi M, Yokoi M. Ishada S, Suzuki S. Kohara M: Hepatitis C virus particle detected by immunclectron microscopic study. J Gen Virol 1994;75:1755-1760.
10. Simntonds P. Holmes ES, Cha TA. Chan SW, McOmish F. Irvine B. Beall E, Yap PL. Kolberg J. Urdea MS: Classification of hepatitis C virus into six major genotypes and a series of sub-types by phylogenetic analysis of the NS-5 region. J Gen Virol 1993:74:2391 -2399.
11. Bonino E. Brunetto MR. Baldi M: Hepatitis C serology. Eur J Gastroenterol Hepatol 1991:3: 580-584.
12. Boudart D. Lucas JC, Muller JY. Le Carrcr D. Planchon B. Harousseau JL: False positive hepatitis C virus antibody tests in paraprotein-aernia. Lancet 1990:63
13. Aach RD, Stevens CE. I lollingcr B, Mosley JW. Peterson DA. Taylor PE, Johnson RG, Barbosa LIE Nemo GJ: Hepatitis C virus infection in posttransfusion hepatitis: An analysis with first- and second-generation assays. N Engl J Med 1991;325:1325-1329.
14. McHutchison JG. Person JL. Govindarajan S. Valinluck B. Gore T. Lee SR. Nelles M. Polito A. Chien D. DiNello R. Quan S. Kuo G. Rede-ker AG: Improved detection of hepatitis C virus antibodies in high-risk populations. Hepatology 1992:15:19-25.
15. Wang Tl I. Wang JT. Lin JT, Sheu JC. Sung JL. Chen DS: A prospective study of post-transfusion hepatitis in Taiwan. J Hepatol 1991:13:38-43.
16. Chien DY. Tabrizi A. McFarland J. Kuo C. Houghton M. Kuo G: Distinct subtypes of hepatitis C virus defined by antibodies directed to the putative core, NS4 and NS5 region polypeptides. Int Symp Viral Hepatitis Liver Dis. Tokyo. May 1993. abstract 346.
17. Brillanti S. Masci C. Ricci P. Miglioli M. Barbara L: Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C. He-patology 1992; 15:998-1001.
18. Yuki N, Hayashi N. Ohkawa K, Hagiwara II. Oshita M. Katayaina K. Sasaki Y, Kasahara A. Fusamoto H. Kamada T: The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C. Hepatology 1995:22:402-406.
19. Vrichnk H. van der Poel CL. Rcesik HW. I laajer HL. Lelie PN: Transmission of hepatitis C virus by anti-HCV-negative blood transfusion: Case report. Vox Sang 1995;68:55-56.
20. Maple PA, McKee T, Desselberger U. Wreghitt TG: Hepatitis C virus infections in transplant patients: Serological and virological investigations. J Med Virol 1994;44:43-48.
21. Gordon SC. Kodali V. Silverman AL. Dmu-ckowski CF. Urdea MS, Chan CS. Wilber JC: Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. Am J Gastroenterol 1994;89:1458-1461.
22. Watanabe S. Kobayashi Y. Konishi M. Yokoi M, Kakchashi R, Kaito M. Suzuki S: Appropriate interferon-alpha therapy for chronic hepatitis C: An assessment by quantitative changes in serum hepatitis C virus-RNA. Intern Med 1993; 32:523-529.
23. Li X. de Medina M, LaRue S. Shao L, SchilT ER: Comparison of assays for HCV RNA. Lancet 1993:343:1174.
24. Okamoto H. Tokita H. Sakamoto M. Horikita M. Kojima M, lizuka H. Mishiro S: Characterization of the genomic sequence of type V (3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993:74:2385-2390.
25. McOmish F, Yap PL. Dow BC. Follet! EAC, Seed C. Keller AJ. Cobain TJ. Krusius T. Kolho E. Naukkarinen R. Lin C, Lai C. Lcong S, Med-gyesi GA. Héjjas M. Kiyokawa H, Fukuda K, Cuypcrs T. Saccd AA. Al-Rashced AM. Lin M. Simmonds P: Geographical distribution of hepatitis C vims genotypes in blood donors: An international collaborative survey.,.J Clin Microbiol 1994:32:884-892.
26. Stuyvcr L, Rossau R. Wyseur A. Duhamel M. Vanderborght B. van Heuvcrswyn II. Macrtens G: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993:74:1093-1102.
27. Kuo G. Choo QL. Aller HJ. Gitnick GT. Rcdcker AG, Purcell Rll. Miamura T, Dicnstag JL. Alter M.I. Stevens CE. Tegtmeier GE. Bonino F. Colombo M. Lee WS, Kuo C. Berger K. Shuster JR. Overby LR. Bradly DW. Houghton M: An assay for circulating antibodies to a major étiologie virus of human non A. non B hepatitis. Science 1989;244:362-364.
28. Van der Poel CL. Rcesink IIW. Lelie PN. Lccnt-vaar-Kuypcrs A, Choo QL. Kuo G. Houghton M: Antihepatitis C antibodies and non-A, non-B post-transfusion hepatitis in the Netherlands. Lancet 1989:6:297-298.
29. Esteban JL Esteban R. Viladomiu L, Lopez-Ta-lavcra JC. Gonzalez A. Hernandez JM. Rogct M. Vargas V, Gcnesca J, Buti M: I lepatitis C virus antibodies among risk groups in Spain. Lancet 1989;vol ii:294-297.
30. Alter HJ, Purcell RH. Shill JW. Mclpoldcr JC. Houghton M. Choo QL. Kuo G: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
31. Myamura T. Saito I. Katayama T, Kikuchi S. Tateda A. Houghton M. Choo QL. Kuo G: Detection of antibody against antigen expressed by molecularly cloned hepatitis C vims cDNA: Application to diagnosis and blood screening for posttransfusion hepatitis. Proe Natl Sci USA 1990:87:983-987.
32. Choo QL. Weiner AJ. Overby LR. Kuo G. Houghton M. Bradley DW: Hepatitis C virus: The major causative agent of viral non A. non B hepatitis. Br Med Bulf 1990:46:423-441.
33. Esteban JL. Gonzalez A. Hernandez JM. Viladomiu L, Sanchez C. Lopcz-Talavera JC. Lucca D. Martin-Vega C. Vidal X. Esteban R. Guardia H: Evaluation of antibodies to hepatitis C vims in a study of transfusion-associated hepatitis. N Engl J Med 1990;323:l107-1112.
34. Feinmann B. Berris B. Ilerst R: Anti-HCV in posttransfusion hepatitis: Deductions from a prospective study.,.J Hepatol 1991; 12:377-381.
35. Bartolotti F. Tagger A. Cadrobbi P. Crivcllaro C. Prcgliasco F. Ribero ML, Alberti A: Antibodies to hepatitis C vims in community-acquired acute non-A. non-B hepatitis. J Hepatol 1991: 12:176-180.
36. Alter MJ, Margolis HS, Krawczynski K. Judson LN. Mares A, Alexander WJ. Hu PY. Miller JK. Gerber MA. Sampliner RE. Meeks EL. Beach MJ: The natural history of community-aquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
37. Mutimcr D. Shaw J. Neubergcr J. Skidmore S. Marlin B, Hubscher S. McMaster P, Elias E: Failure to incrimate hepatitis B. hepatitis C. and hepatitis E viruses in the aetiology of fulminant non-A. non-B hepatitis. Gut 1995:36:433-436.
38. Mattsson L. Grillner L. von Sydow M. Bergdahl S. Weiland O: Seroconversion to hepatitis C virus antibodies in patients with acute posttrans-fusion non-A. non-B hepatitis in Sweden. Infection 1991;19:309-312.
39. Wang JT, Wang TI I. Lin JT. Sheu JC. Sung JL. Chen DS: Hepatitis C virus in a prospective study of posttransfusion non-A. non-B hepatitis in Taiwan. J Med Virol 1990:32:83-86.
40. Nishioka K. Watanabe J. Furata S. Tanaka E. Suzuki H. Lino S. Tsuji T. Yano M. Kuo G. Choo QL. Houghton M. Oda T: Antibody to the hepatitis C vims in acute and chronic liver disease in Japan. Liver 1991;11:65-70.
41. Tremolada F. Casarin C. Tagger A. Ribero ML. Rcaldi G. Alberti A, Ruol A: Antibody to hepatitis C vims in post transfusion hepatitis. Ann Intern Med 1991;114:277-281.
42. Prohaska W. Wolff C. Lechler E. Kleesiek K: High rate of false positives in blood donor screening for antibodies to hepatitis C virus: Cause of underestimation of vims transmission rate'.’ Klin Wochenschr 1991:69:294-296.
43. Widell A. Mansson AS. Sundstrom G. Hansson BG. Nordenfclt E: Hepatitis C vims RNA in blood donor sera detected by the polymerase chain reaction: Comparison with supplementary hepatitis C antibody assays. J Med Virol 1991:35:253-258.
44. Boxall E. Skidmore S, Evans C. Nightingale S: The prevalence of hepatitis B and C in an antenatal population of various ethnic origins. Epidemiol Infect 1994:113:523-528.
45. Larsen J, Heiland G. Skaug K. Mac-land A: Vi-rushepatitt og blodtransfusjon. Tidsskr Nor Lacgcforcn 1991;11:825-828.
46. Ndumbc PM. Skalsky I. Joller Jemelka HI: Se-roprcvalence of hepatitis and HIV infection among rural pregnant women in Cameroon. APMIS 1994:102:662-666.
47. Saleh MG. Pereira LM, Tibs CJ. Ziu M. al Fituri MO. Williams R. McFarlanc IG: High preva-lenceof hepatitis C vims in normal Libyan population. Trans R Soc Trop Med Flyg 1994:88: 292-294.
48. Irving WL. Neal KR, Underwood JCE, Simmonds PN, James V. on behalf ofTrent Regional 1 lepatitis C Vims Study Group: Chronic hepatitis in United Kingdom blood donors infected with hepatitis C virus. BMJ 1994:308:695-696.
49. Nordoy I. Schrumpf E, Elgjo K. Flesland O, Andersen Glendc J, Orjasaeter FI. Sicbke JC: Liver disease in anti-hepatitis C vims positive Norwegian blood donors. Scand J Gastroenterol 1994:29:77-81.
50. Alberti A. Morsica G, Chemello L, Cavallctto D. Noventa F, Pontisso P. Ruol A: Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992:340: 697-698.
51. Yuki N. Hayashi N. Takehara T. Hagiwara H. Hiramatsu N. Naito M. Kawanishi Y. Katayama K. Kasahara A. Fusamoto II. Kamada T: Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors. Am J Gastroenterol 1994;89:1462-1466.
52. Vrielink H. van der Poe I CL. Reesink IIVV. Zaaijer H. Scholtcn E. Krcmcr LC. Cuypcrs HT. Lelic PN. van Ocrs MH: Look-back study of infectivity of anti-IICV IT.ISA-positive blood components. Lancet. 1995:345:95-96.
53. Tong MJ. el Taira NS. Reikes AR. Co RL: Clinical outeomcrs after transfusion-associated hepatitis C. N Engl J Med 1995:332:1463-1466.
54. Sakamoto N. Enomoto N, Marumo F. Sato C: Prevalence of hepatitis C virus infection among long tenu hemodialysis patients: Detection of hepatitis C virus RNA in plasma.,.J Med Virol 1993;39:l1-15.
55. Hussein MM. Mooij JM. Roujouleh H. el Saved IT: Observations in a Saudi-Arabian dialysis population over a 13-year period. Nephrol Dial Transplant 1994;9:1072-1076.
56. Dussol B. Berthczcnc P. Brunet P. Roubicek C. Berland Y: Hepatitis C virus infection among chronic dialysis patients in the south of France: A collaborative study. Am J Kidney Dis 1995: 25:399-404.
57. Ng YY. Lee SD. Wu SC. Yang WC, Chiang SS. Huang TP: Antibodies to hepatitis C virus in uremic patients on continuous ambulatory peritoneal dialysis.,.J Med Virol 1991:35:263-266.
58. Pol S. Romeo R. Zins B. Lebkiri B. Bcrthclot P. Brechot C: High frequency of ITCV viremia in anti ITCV positive hemodialyzed patients (abstract), Hepatology 1992; 16:218.
59. Gerritzcn A. Klehr U, Scholl B. Kaiser R. Lutzkc G. Fcrber I, Schnewcis KE: Infcktions-risiko durch Hepatitis C Virus bei der Haemo-dialysc (abstract). Klin Wochcnschr 1992: 69(suppl 28):36.
60. Eabrizi E. Lunghi G, Guarnori I. Raffacle L. Crcpaldi M. Pagano A. Locatelli F: Incidence of seroconversion for hepatitis C virus in chronic haemodialysis patients: A prospective study. Nephrol Dial Transplant. 1994:9:1611-1615.
61. Dienstag H. Stevens CE, Szmuncss W: The epidemiology of non-A. non-B hepatitis: Emerging patterns: in: Gercty RJ (ed): Non-A. Non-B Hepatitis. New York. Academic Press. 1981, pp 119-137.
62. Lok ASF. Chan TM. Chan R. Cheng IKP: ITCV infection in hemodialysis (HD) patients: A comparative study using I st and 2nd generation EIA for anti-I ICV and PCR for HCV-RNA (abstract). Gastroenterology 1992:102:845.
63. Chan TM. Lok ASF. Cheng IKP. Chan RT: Prevalence of hepatitis C-virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assay. I Ic-patology 1993:17:5-8.
64. Jadoul M. Cornu C, van-Ypersele-de-Strihou C: Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study: The UCL Collaborative Group. Kidney Int 1993:44:1322-1326.
65. I lartwcll P. Willson R. Hart J. Johnson I: Chronic hepatitis C. glomerulonephritis, and alpha in-terferon-2b (abstract). Gastroenterology 1992: 102:818.
66. Johnson R.I. Pretch DR, Yaniabe IT. Hart J. Bac-chi CE. Hartwcll P. Cotiser WG, Corey L. Weiter MIL. Alpers CE. Willson R: Membrane proliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993:328: 465-470.
67. Johnson RJ. Gretch DR. William GC, Alpers CE. Wilson J. Chung M, Hart J. Willson R: I lep-atitis C virus-associated glomerulonephritis: Effect of «-interferon therapy. Kidney Int 1994; 46:1700-1704.
68. Doutrelepont JM. Adler M. Willems M. Durez P, Yap SH: Hepatitis C infections and membra-noproliferativc glomerulonephritis. Lancet 1993:341:317.
69. I larlc JR. Disdier P. Dussol B, Bolla G, Casanova P. Wcillcr PJ: Membranoproliferativeglomerulonephritis and hepatitis C infection. Lancet 1993:341:904.
70. DAmico G. Fomasieri A: Cryoglobulinémie glomerulonephritis: A membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1995:25:361-369.
71. Iloofnagle JIT. Mullen KD. Jones DB. Rustgi V. DiBisceglie A. Peters M. Waggoner JG. Park Y. Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N Engl J Med 1986:315:1575-1578.
72. Davis DE. Baiart LA, Schiff ER, Lindsay K, Bodcnheimcr HI, Perillo RP. Carey W. Jacobson IM. Payne J. Dienstag JL. Van Thiel DH. Tamburro C. Lcfkowitch J. Albrecht J. Mcsehievitz C. Ortego TJ. Gibas A: Treatment of chronic hepatitis C with recombinant interferon alia: A multicenter randomized, controlled trial. N Engl J Med 1989:321:1501-1506.
73. DiBisceglie AM, Martin P. Kassianidcs C. Lis-kcr-Molman M. Murray L, Waggoner JG, Goodman Z. Banks SM. I loofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C: A randomized double-blind placebo-controlled trial. N Engl.J Med 1989:321: 1506-1510.
74. Marcellin P. Boyern Giostra E. Degott C. Couroucc AM. Dcgos F. Copperere IT. Cales P. Couzigou P. Benhamou JP: Recombinant human «-interferon in patients with chronic non-A. non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991; 13:393-397.
75. Hoofnagle JH. DiBisceglie AM. Shindo M: Antiviral therapy of hepatitis C Present and future. J epatol 1993:17:(suppl 3):S130-S136.
76. Takehara T. ITayashi N. Mita E, Hagiwara H. Ueda K. Katayama K. Kasahara A. Fusamoto IT, Kamada T: Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implications for hepatitis C virus replication in infected tissue. Hepatology 1992:15:387-390.
77. Enomoto N, Sakuma I. Asahina Y. Kurosaki M. Murakami T. Yamamoto C. Izumi N, Marumo F. Sato C: Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus H.J Tin Invest 1995:96:224-230.
78. Fried MW, Hoofnagle JH: Therapy for hepatitis C. Semin Liver Dis 1995:15:82-91.
79. Brillanti S. Parson J. Foli M. Whitby K. Deavillc R. Masci C. Miglioli M. Barbara L: A pilot study of combination therapy with ribavirin plus mterferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-817.
80. Reichard O. Andersson J. Schwarcz R. Weiland O: Ribavirin treatment for chronic hepatitis C. Lancet 1991:337:1058-1061.
81. DiBisceglie AM. Shindo M. Fong TL, Fried MW. Swain MG, Bergasa NV. Axiotitis CA, t Waggoner JG. Park Y. Hoofnagle JH. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992:16:649-654.
82. Kakumu S. Yoshioka K. Wakita T. Ishikawa T. Takayanagi M. Higashi Y: A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993: 105:507-512.
83. Rassam S. Dushciko GM: Ribavirin treatment of chronic hepatitis C: A phase I study (abstract). Hepatology 1992:16:585.
84. Camps J. Garcia N. Riczu-Boj JL. Civeira MP. Prieto J: Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993:19:408-412.
85. Bodcnheimcr H. Lindsay KL. Davis GL. Lewis HI, Thing SN. Mahaney K, Seeff L: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial (abstract). Hepatology 1994:20:207.
86. Gane EJ. Tibbs CJ. Ramage JK. Portmann BC, Williams R: Ribavirin for hepatitis C infection following liver transplantation. Transplant Int 1995:8:61-64.
87. Duane R. Huraib S. Said R, Abdcl-Kadir A, Sullivan S. Chaballout A, Sbeih F. Mughal T: Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney 1995:25:40-45.
88. Ellis ME. Alfurayh O, Halim MA, Sieck JO, Ali MA. Bernvil SS. Ali II. Barri Y. Ayub A, Al-Fadda M: Chronic non-A, non-B hepatitis com-plicated by end-stage renal failure treated with recombinant interferon alpha.,.J Hepatol 1993: 18:210-216.
89. Koenig P. Vogel W. Umlauft F, Weyrer K. Prom-megger R. Lhotta K. Neyer U, Stummvoll HK, Gruenewald K: Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994:45:1507-1509.
90. Pol S. Thiers V. Carnot F. Zins B. Romeo R. Berthelot P. Brcchot C: Efficacy and tolerance of a-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995:47: 1412-1418.